Gliclazide compatibility with some common chemically reactive excipients; using different analytical techniques
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Evaluation of drug-excipient compatibility is one of the basic steps in the preformulation of pharmaceutical dosage forms. Some reactive excipients have been known so far which may cause stability problems for drug molecules in pharmaceutical dosage forms. The aim of this study was to evaluate drugexcipient compatibility of gliclazide with some common pharmaceutical excipients, known for their ability to incorporate in drug-excipient interactions. Binary mixtures were prepared using lactose, magnesium stearate, polyvinylpyrrolidone, sodium starch glycolate, polyethylene glycol 2000 and dicalcium phosphate. Based on the results; gliclazide was incompatible with all tested excipients; but not with dicalcium phosphate. DSC (Differential Scanning Calorimetry) results were in accordance with HPLC (High Pressure liquid chromatography) data and were more predictive than FTIR (Fourier Transform Infrared Spectroscopy). Drug and reactive excipients incompatibility was fully discussed and documented. It is advisable to avoid incompatible excipients or carefully monitor the drug stability when incorporating such excipients in final formulation designs.
Abstract
Evaluation of drug-excipient compatibility is one of the basic steps in the preformulation of pharmaceutical dosage forms. Some reactive excipients have been known so far which may cause stability problems for drug molecules in pharmaceutical dosage forms. The aim of this study was to evaluate drugexcipient compatibility of gliclazide with some common pharmaceutical excipients, known for their ability to incorporate in drug-excipient interactions. Binary mixtures were prepared using lactose, magnesium stearate, polyvinylpyrrolidone, sodium starch glycolate, polyethylene glycol 2000 and dicalcium phosphate. Based on the results; gliclazide was incompatible with all tested excipients; but not with dicalcium phosphate. DSC (Differential Scanning Calorimetry) results were in accordance with HPLC (High Pressure liquid chromatography) data and were more predictive than FTIR (Fourier Transform Infrared Spectroscopy). Drug and reactive excipients incompatibility was fully discussed and documented. It is advisable to avoid incompatible excipients or carefully monitor the drug stability when incorporating such excipients in final formulation designs.
참고문헌 (22)
- S. S. Bharate, , J. Excip. Food. Chem, 1(3), pp.3~26 (2010)
- P. M. Adhikari, , Journal of Clinical and Diagnostic Research, 1(5), pp.440~443 (2007)
- F. Lotfipour, , Iranian Journal of Pharmaceutical Research : IJPR, 14(4), pp.1015~1029 (2015)
- F. Monajjemzadeh, , Adv. Pharm. Bull, 4(4), pp.329~338 (2014)
- M. R. S. Shadbad, , AAPS PharmSciTech, 17, pp.1491~1499 (2016)
- S. K. Sharma, , International Journal of PharmTech Research, 6(2), pp.607~622 (2014)
- F. Ghaderi, , Journal of Thermal Analysis and Calorimetry, 123(3), pp.2081~2090 (2016)
- F. Monajjemzadeh, , J. Mol. Pharm. Org. Process Res, 3, pp.e121~ (2015)
- G. Kirtansinh, , International Journal of Pharmaceutical & Biological Archive, 2(5), pp.1319~1326 (2011)
- R. C. Rowe, "Handbook of Pharmaceutical Excipients" (2006), Pharmaceutical press
- A. T. Serajuddin, , Journal of Pharmaceutical Sciences, 88(7), pp.696~704 (1999)
- F. Monajjemzadeh, , Journal of Molecular Pharmaceutics & Organic Process Research, 2(3), pp.e117~ (2014)
- F. Monajjemzadeh, , Pharmind : Die Pharmazeutische Industrie, 73(1), pp.174~177 (2011)
- F. Monajjemzadeh, , European Journal of Pharmaceutics and Biopharmaceutics, 73(3), pp.404~413 (2009)
- F. Ghaderi, , Journal of Food and Drug Analysis, 25(3), pp.709~716 (2017)
- F. Ghaderi, , Journal of Thermal Analysis and Calorimetry, 130(3), pp.1417~1427 (2017)
- G. Bansal, , Chromatographia, 66(9-10), pp.751~755 (2007)
- S. K. Branch, , Journal of Pharmaceutical and Biomedical Analysis, 38(5), pp.798~805 (2005)
- M. Windholz, "The Merck Index: An Encyclopedia of Chemicals and Drugs" (2013), Royal Society of Chemistry
- P. Niguram, , Drug Development and Industrial Pharmacy, 46(2), pp.209~218 (2020)
- M. Ecaterina, , The Moldovan Medical Journal, 63(4), pp.35~42 (2020)
- Y. Wu, , AAPS PharmSciTech, 12(4), pp.1248~1263 (2011)